Isabella Ciccone, MPH

Satsuma’s STS101 nasal powder becomes the first and only DHE nasal powder for the acute treatment of migraine with or without aura in adults.

Explore the latest advancements in cell and gene therapies for Parkinson disease, featuring cutting-edge treatments and clinical trial updates from top innovators in the field.

The REGENERATE-PD trial is a phase 2 study assessing the safety and efficacy of the investigational gene therapy AB-1005 in patients with moderate-stage Parkinson disease.

The chief scientific officer of the Parkinson’s Foundation talked about how broad genetic testing through PD GENEration is uncovering valuable prognostic and diagnostic insights in Parkinson disease. [WATCH TIME: 4 minutes]

A new meta-analysis revealed that the efficacy of MRI-guided focused ultrasound decreased over time in essential tremor, with sensory symptoms and unsteadiness as common adverse effects.

The division chief of neurology at Nemours Children’s Hospital discussed evolving surgical techniques, neuromodulation therapies, and precision medicine approaches for complex epilepsy cases. [WATCH TIME: 5 minutes}

A recently published meta-analysis reported that fatty acid supplementation, particularly omega-3, may significantly reduce severity, duration, and frequency of migraine in patients.

Bruce Bebo, PhD, and Amit Bar-Or, MD, FRCPC, FAAN, FANA, discussed the impact of the John Dystel Prize on multiple sclerosis research and its role in shaping future clinical advancements.

Sumaira Ahmed, founder and executive director of The Sumaira Foundation, discussed how FDA-approved therapies transformed the NMOSD treatment landscape and highlighted ongoing challenges in patient care.

The founder and executive director of the Sumaira Foundation emphasized the critical role of lifestyle factors such as sleep, exercise, and nutrition for maintaining brain health in patients with NMOSD. [WATCH TIME: 3 minutes]

The neuromuscular neurologist at Nemours Children's Hospital in Florida talked about the increasing role of genomic medicine in neuromuscular disorders. [WATCH TIME: 4 minutes]

The director of sleep medicine at Nemours Children's Health in Florida talked about the growing treatment landscape for pediatric sleep disorders and the vital role of family-centered, multidisciplinary care. [WATCH TIME: 5 minutes]

The switch from 1 anti-CGRP monoclonal antibody to another led to a significant reduction in monthly headache days, regardless of target mechanism, dose history, or time between treatments.

The system has been previously recognized with breakthrough device designation by the FDA, emphasizing its potential to enhance epilepsy care through more effective diagnosis and management.

The director of sleep medicine at Nemours Children's Health in Florida talked about the growing role of multidisciplinary care and novel therapies in managing pediatric sleep disorders.

Results from the open-label extension of a phase 3 trial showed that treatment with ravulizumab sustained clinical benefits for up to 4 years in patients with generalized myasthenia gravis.

The division chief of neurology at Nemours Children’s Hospital spoke on the need for timely referrals to epilepsy centers for patients with drug-resistant epilepsy. [WATCH TIME: 5 minutes]

The chief of ophthalmology at the Doheny Eye Institute discussed decades of research uncovering how Alzheimer can impact visual function and how retinal imaging may advance diagnosis. [WATCH TIME: 13 minutes]

Data suggest no significant differences in comorbidity rates in a newly published study, highlighting dosing challenges and treatment patterns in patients receiving immediate-release sodium oxybate.

The resident in the Department of Neurology at NYU Langone Health discussed the preliminary findings of a 9-month study on lecanemab recently presented at the 2025 AAN Annual Meeting. [WATCH TIME: 2 minutes]

In a randomized cross-over trial, 4 of 5 commonly used drugs for idiopathic intracranial hypertension reduced intracranial pressure; however, also exacerbated cognitive issues.

The executive vice president of research at the National MS Society talked about how the award continues to honor transformative multiple sclerosis research and inspire the next generation of investigators. [WATCH TIME: 5 minutes]

The chief scientific officer of the Parkinson’s Foundation discussed the foundation’s efforts to integrate whole genome sequencing into PD GENEration and expand access across diverse global populations. [WATCH TIME: 4 minutes]

A recently published phase 1 study revealed that coadministration of intranasal zavegepant with an oral contraceptive did not lead to clinically significant changes in drug exposure.

Although the study reported no evidence linking human leukocyte antigen alleles to migraine, the findings were not replicated, suggesting the HLA system may not be involved in migraine susceptibility.

A duo of neurology experts from Feinberg School of Medicine talked about the diagnostic challenges, evolving understanding, and clinical implications of paraneoplastic neurological syndromes. [WATCH TIME: 3 minutes]

The director of NYU Langone's Multiple Sclerosis Comprehensive Care Center discussed the importance of early, high-efficacy treatment for pediatric MS. [WATCH TIME: 3 minutes]

In late-breaking findings from the TRANQUIL study presented at AAN 2025, the wearable demonstrated significant improvements in tremor reduction and daily functioning over a sham device.

The senior director of mission programs at The ALS Association discussed how the thinkALS Toolkit can aid general neurologists in identifying and referring suspected cases more efficiently. [WATCH TIME: 5 minutes]

The physician assistant at UCSF Movement Disorder and Neuromodulation Center reflected on the value of AMDAPP in fostering professional connection, education, and patient-centered care among movement disorder APPs. [WATCH TIME: 3 minutes]